HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Atsushi Fukatsu Selected Research

1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitol

11/2018Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
3/2018Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
1/2018Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
4/2016Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
1/2016Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
7/2015Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.
4/2015Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
1/2015Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
7/2014Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
7/2014Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Atsushi Fukatsu Research Topics

Disease

12Type 2 Diabetes Mellitus (MODY)
11/2018 - 03/2002
10Glomerulonephritis
01/2016 - 12/2005
9Diabetic Nephropathies (Diabetic Nephropathy)
01/2022 - 08/2005
8Body Weight (Weight, Body)
04/2016 - 06/2005
6Nephrotic Syndrome (Syndrome, Nephrotic)
12/2012 - 03/2002
5Albuminuria
01/2022 - 05/2003
3Hypoglycemia (Reactive Hypoglycemia)
01/2018 - 01/2015
3Proteinuria
12/2012 - 03/2002
3Nephritis
12/2012 - 03/2007
3Acute Kidney Injury (Acute Renal Failure)
02/2012 - 12/2008
3Brain Death (Brain Dead)
10/2006 - 06/2004
3End Stage Liver Disease
10/2006 - 06/2004
2Fibrosis (Cirrhosis)
01/2022 - 10/2011
2Hypertension (High Blood Pressure)
04/2016 - 01/2009
2POEMS Syndrome (Syndrome, POEMS)
02/2012 - 06/2002
2Chronic Kidney Failure (Chronic Renal Failure)
01/2011 - 01/2006
2Lipoid Nephrosis (Glomerulonephritis, Minimal Change)
01/2008 - 03/2002
2Edema (Dropsy)
03/2007 - 06/2005
2Thrombosis (Thrombus)
10/2006 - 08/2005
2Disseminated Intravascular Coagulation
10/2006 - 08/2005
2Hypertrophy
08/2005 - 05/2003
2Hyperuricemia
03/2005 - 09/2003
2Hyperlipidemias (Hyperlipidemia)
05/2004 - 03/2002
1Hypoxia (Hypoxemia)
01/2022
1Obesity
04/2016
1Autosomal Dominant Polycystic Kidney (ADPKD)
01/2016
1Weight Gain
07/2015
1Myocardial Infarction
01/2014
1Stroke (Strokes)
01/2014
1Hemorrhagic Stroke
01/2014
1Ischemic Stroke
01/2014
1Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal)
12/2012
1IGA Glomerulonephritis (IGA Nephropathy)
12/2012
1Hypercholesterolemia
04/2012
1Anemia
10/2011
1Multiple Myeloma
05/2011
1Disease Progression
05/2011
1Renal Insufficiency (Renal Failure)
05/2011
1MELAS Syndrome (Syndrome, MELAS)
01/2011

Drug/Important Bio-Agent (IBA)

111,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA
11/2018 - 07/2014
8Glucose (Dextrose)FDA LinkGeneric
01/2022 - 07/2014
7Proteins (Proteins, Gene)FDA Link
12/2012 - 04/2002
4Sodium-Glucose Transport ProteinsIBA
01/2022 - 07/2014
4CreatinineIBA
12/2012 - 01/2006
4Messenger RNA (mRNA)IBA
12/2005 - 04/2002
3Sodium-Glucose Transporter 2 InhibitorsIBA
01/2022 - 04/2016
3Insulin (Novolin)FDA Link
01/2018 - 08/2007
3Blood Glucose (Blood Sugar)IBA
10/2016 - 08/2005
3CollagenIBA
10/2016 - 06/2007
3Cyclosporine (Ciclosporin)FDA LinkGeneric
08/2009 - 03/2002
3Streptozocin (Streptozotocin)FDA Link
05/2008 - 05/2003
37,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)IBA
10/2006 - 06/2004
2SodiumIBA
03/2018 - 04/2016
2Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
04/2016 - 01/2016
2Hypoglycemic Agents (Hypoglycemics)IBA
07/2015 - 01/2015
2CalciumIBA
01/2014 - 03/2006
2Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
12/2012 - 01/2006
2oxidized low density lipoproteinIBA
04/2012 - 03/2002
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2012 - 06/2002
2Prednisolone (Predate)FDA LinkGeneric
05/2011 - 01/2008
2Antigen-Antibody Complex (Immune Complex)IBA
08/2009 - 03/2006
2Uric Acid (Urate)IBA
12/2008 - 03/2005
2Dacarbazine (DIC)FDA LinkGeneric
10/2006 - 08/2005
2MethylprednisoloneFDA LinkGeneric
10/2006 - 08/2005
2Actins (F Actin)IBA
09/2006 - 04/2006
2Warfarin (Coumadin)FDA LinkGeneric
08/2005 - 05/2003
1CanagliflozinIBA
01/2022
1LiraglutideFDA Link
03/2018
1Glucagon-Like Peptide-1 ReceptorIBA
03/2018
1Collagen Type IV (Type IV Collagen)IBA
01/2016
1Matrix Metalloproteinases (MMPs)IBA
01/2016
1ThiazolidinedionesIBA
07/2015
1Hemoglobins (Hemoglobin)IBA
07/2014
1Phosphates (Orthophosphate)IBA
01/2014
1MineralsIBA
01/2014
1Amyloid (Amyloid Fibrils)IBA
12/2012
1InterferonsIBA
04/2012
1LDL Lipoproteins (beta Lipoproteins)IBA
04/2012
1Interleukin-12 (IL 12)IBA
04/2012
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2012
1Carrier Proteins (Binding Protein)IBA
01/2012
1Selective Estrogen Receptor Modulators (SERM)IBA
10/2011
1TamoxifenFDA LinkGeneric
10/2011
1Myelin P0 Protein (Myelin Protein Zero)IBA
10/2011
1Hormones (Hormone)IBA
10/2011
1ErythropoietinFDA Link
10/2011
1Thalidomide (Thalomid)FDA Link
05/2011
1Platelet-Derived Growth FactorIBA
03/2011
1Monoclonal AntibodiesIBA
03/2011

Therapy/Procedure

12Therapeutics
01/2018 - 05/2004
4Glycemic Control
03/2018 - 07/2014
3Renal Dialysis (Hemodialysis)
01/2014 - 09/2009
3Liver Transplantation
10/2006 - 06/2004
2Blood Component Removal (Apheresis)
04/2012 - 03/2002
2Kidney Transplantation
08/2011 - 08/2009
2Transplantation
08/2009 - 06/2004
2Splenectomy
10/2006 - 08/2005
1Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
02/2012
1Drug Therapy (Chemotherapy)
05/2011
1Intravenous Injections
03/2011